Wharton's Jelly and Exosome Supplier for Sarasota Orthopedic Practices

How Sarasota orthopedic practices qualify a biologics vendor

Orthopedic practices and ambulatory surgery centers typically run vendor qualification through a combination of practice administration and a designated medical director before any product is approved for use in the clinic. That review generally covers the supplier's donor eligibility process, processing and testing documentation, and the chain of custody from recovery to shipment. Practices in the Southeast often also confirm that a supplier can produce a certificate of analysis and lot release record for each shipment, since those documents are what a practice keeps on file alongside its own procurement records.

• Certificate of analysis and lot release record per shipment
• Donor eligibility and serology testing summary
• Chain-of-custody documentation from recovery through delivery

NPI-verified accounts and ordering

Precision Biologics opens accounts only for licensed professionals and requires a National Provider Identifier before an order is processed. For a practice in Sarasota, that means the office contact who sets up the account should have the practice's NPI and the name of the supervising physician or medical director on hand. Once an account is verified, ordering and reorder scheduling run through the same point of contact, which keeps lot tracking consistent on the clinic side.

Cold-chain and shelf-stable shipping to the Southeast

Cryopreserved Wharton's jelly and exosome formats ship overnight on dry ice in validated containers and are tracked to confirm temperature control on arrival. Lyophilized formats ship shelf-stable and do not require a freezer on receipt, which simplifies intake for a surgery center without dedicated cryogenic storage. Either way, a Sarasota practice should have a written receiving procedure that logs the lot number against the shipment at the moment it arrives, since that lot number is what connects the product to its documentation later.

Verification and account setup support

Florida practices considering regenerative biologics should independently verify any product's regulatory posture with the Florida Board of Medicine and their own counsel; Florida's SB 1768, effective July 1, 2025, addresses physician use of certain non-FDA-approved stem cell therapies in limited contexts and does not change federal FDA requirements for the products themselves. Precision Biologics supports this review by making registration and licensure documentation, certificates of analysis, and donor eligibility summaries available to verified accounts, and by offering a peer-to-peer call between a requesting physician and a physician familiar with the documentation, limited to reviewing paperwork rather than clinical guidance.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.